Abnova (Taiwan) Corporation manufactures and sells various recombinant proteins and antibodies. The company’s products portfolio includes SARS-CoV/CoV-2 DNA, RNA, proteins/peptides, lysates/slides, Ab pairs/kits, Ab arrays, polyclinic antibody, beads/dyes, in situ hybridization products, systems, and automations. It also offers MaxPab, monoclonal, polyclonal, recombinant, conjugate, secondary/tag, IHC/pathology, and circulating rare cell antibodies. In addition, the company provides integrated solutions and services, including gene synthesis and cytogenetics; peptide services, protein expression, and conjugations; antibody production; and assay development services. It serves academic, research institutions, and pharmaceutical factories. Abnova (Taiwan) Corporation was founded in 2002 and is headquartered in Taipei, Taiwan.
Metrics to compare | 4133 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4133PeersSector | |
---|---|---|---|---|
P/E Ratio | −235.4x | 23.8x | −0.6x | |
PEG Ratio | 2.14 | 0.15 | 0.00 | |
Price/Book | 1.3x | 2.7x | 2.6x | |
Price / LTM Sales | 4.3x | 4.3x | 3.3x | |
Upside (Analyst Target) | - | 11.1% | 37.4% | |
Fair Value Upside | Unlock | 3.4% | 4.5% | Unlock |